摘要
目的 评价左氧氟沙星治疗肺结核的疗效、适宜剂量和在我国应用的前景。方法 97例初治菌阳肺结核随机分为治疗组 ( 2HL2 V/4HL2 、50例 )和对照组 ( 2HL2 Z/4HL2 、4 7例 )进行短程化疗。结果 治疗组和对照组 2个月痰菌阴转率分别为 94 0 %和 83 0 % ;满疗程痰菌阴转率分别为 98 0 %和 97 9%。胸部X线所见 ,治疗组和对照组病灶吸收分别为 98 0 %和 95 7% ,两组分别有 73 1 %和 50 0 %的空洞闭合。治疗组和对照组不良反应发生率分别为 1 3 2 %和 7 8%。结论 左氧氟沙星是一种新的有效的、安全的抗结核药物。
Objective To assess antituberculosis efficacy,suitable dose and application perspective of levofloxacin in China.Methods 97 new smear positive pulmonary tuberculosis patients were randomly allocated into treatment group(50 cases,receiving 2HL 2V/4HL 2 regimen)and controls(47 cases,2HL 2Z/4HL 2)for observation.Results The sputum negative conversion rates at the 2nd month in treatment group and the controls were 94.0% and 83.0% respectively,and at the end of chemotheraphy 98.0% and 97.7% Chest radiography showed remarkable improvement.The resolution of pulmonany lesions in the treatment group and the controls accounted for 98.0% and 95.7% respectively,with cavity closure rates of 73.1% in the treatment group and 50.0% in the controls.The drug adverse reaction rates were 13.2% in the treatment group and 7.8% in the controls.Conclusion Levofloxacin is a new effeitive and safety antituberculosis drug.
出处
《中国防痨杂志》
CAS
2000年第2期63-65,共3页
Chinese Journal of Antituberculosis
关键词
肺结核
药物疗法
左氧氟沙星
Tuberculosis,pulmonany Drug therapy Levofloxacin
